This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

EYLEA® (aflibercept) 8 mg

Safety Profile in Diabetic macular oedema (DME)

Safety profile

The reassurance of treating your patients with the tried-and-trusted aflibercept molecule

In PULSAR and PHOTON, EYLEA 8mg demonstrated a safety profile consistent with EYLEA 2mg from baseline through Week 96:^*

^{* EYLEA (aflibercept) 2mg was dosed at fixed Q8 intervals after 3 (nAMD) or 5 (DME) initial monthly injections.}

PHOTON safety

Adverse events in patients receiving EYLEA 8mg were consistent with EYLEA 2mg

PHOTON: most frequent AEs through Week 48

^{Adapted from Do D. 2023.}

^{* Any ocular treatment-emergent AE in the study eye.}
^{† Treatment-emergent events.}
^{‡ All events.}

Dosing

Discover proactive dosing in nAMD and DME

Mechanism of Action (MoA)

Discover more about the MoA of EYLEA 8mg

Safety Profile

Explore the safety profile of EYLEA 8mg in nAMD and DME

Abbreviations

2Q8

^{, 2 mg every 8 weeks;}^8Q12^{, 8 mg every 12 weeks;}^8Q16^{, 8 mg every 16 weeks;}^AE^{, adverse event;}^APTC^{, Anti-Platelet Trialists’ Collaboration;}^DME^{, diabetic macular oedema;}^IOI^{, intraocular inflammation;}^IOP^{, intraocular pressure;}^MoA^{, mechanism of action;}^nAMD^{, neovascular (wet) age-related macular degeneration;}^Q8^{, every 8 weeks;}^SAE^{, serious adverse event;}^SAF^{, safety analysis set;}^TEAE^{, treatment-emergent adverse event.}

PP-EYL_8mg-IE-0157-1 | January 2026

References

1
Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
2
Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
3
Korobelnik J-F. Aflibercept 8 mg in patients with neovascular age-related macular degeneration: Phase 3 PULSAR trial 96-week results. AAO. 3–6 November 2023. San Francisco, USA. Oral presentation.
4
Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
5
EYLEA® 114.3 mg/mL Summary of Product Characteristics.
6
Lanzetta P, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.